GET STARTED Washington Correspondent Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter “D.C. Diagnosis.” TAMWORTH, N.H. — Rep. Chris Pappas strode into the Tri-County Cap, a nondescript office building nestled between a propane company and a masonry supply yard, with a laundry list of ideas for lowering prescription drugs. But what his constituents really wanted to know was whether anything would ever change.Pappas was holding a town hall on prescription drug affordability, one of his first since being elected to the House of Representatives in November. Within minutes of taking the mic, Pappas demonstrated how well he’d prepared for the event: He railed against existing laws blocking Medicare from negotiating drug prices as “a giveaway to the drug industry that should never [have] happened” and implored the government to force drug makers to bargain. He called drug ads on TV “just a waste” and said they should be banned. Rep. Chris Pappas (D-N.H.) Charles Krupa/AP What’s included? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. About the Author Reprints Log In | Learn More What is it? Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED Tags Congressdrug pricingpolicySTAT+ Nicholas Florko [email protected] Despite their pledges, Democrats haven’t yet lowered drug prices. Here’s how they’re explaining themselves @NicholasFlorko Politics By Nicholas Florko Aug. 19, 2019 Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.